Nexplanon (Etonogestrel)

Etonogestrel, released from the implant, binds to progesterone receptors in the brain, suppressing the luteinizing hormone surge and thereby preventing ovulation. It also thickens cervical mucus and alters the endometrial lining, creating an environment that is unfavorable for sperm penetration and implantation.

The Nexplanon implant contains a fixed 68 mg of etonogestrel that is released at a low, steady rate. The exact dosing schedule is determined by the prescribing clinician, who inserts a single implant that provides contraceptive effect for up to three years.

Nexplanon is contraindicated in pregnancy (Category X) and must not be inserted in a pregnant woman. Women who become pregnant while using the implant should seek immediate medical advice. Limited data suggest that breastfeeding is not a contraindication, but clinicians should evaluate individual risk‑benefit considerations.

To place an order, submit an enquiry on the Nexplanon product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with oral contraceptive pills, Nexplanon eliminates daily adherence and provides up to three years of protection from a single procedure. Relative to other implants such as Implanon, Nexplanon offers a similar efficacy profile but is marketed under a different brand name. Overall, it delivers higher continuation rates and lower user‑error risk than short‑term methods.

Nexplanon should be stored at ambient temperature, preferably below 25 °C, in its original sealed packaging. Protect the implant from moisture, direct sunlight and extreme temperatures. Do not freeze or expose it to temperatures above the recommended range, as this may affect the drug release characteristics.

A qualified healthcare professional inserts Nexplanon subdermally in the inner side of the upper arm using a sterile applicator. The procedure is performed in an outpatient setting, takes only a few minutes, and does not require anesthesia. After insertion, the implant remains in place for up to three years before removal or replacement.

Serious risks include rare thromboembolic events such as deep‑vein thrombosis, severe allergic reactions that may manifest as anaphylaxis, and the possibility of ectopic pregnancy if contraception fails. Users should seek immediate medical attention for signs of chest pain, sudden shortness of breath, severe rash, or abnormal bleeding.

Nexplanon is contraindicated in women with active breast cancer, known or suspected pregnancy, severe liver disease, or a history of thromboembolic disorders. It should also be avoided in individuals who are hypersensitive to etonogestrel or any component of the implant.